CN115003319B - 用于治疗癌症的方法和组合物 - Google Patents

用于治疗癌症的方法和组合物

Info

Publication number
CN115003319B
CN115003319B CN202080092637.1A CN202080092637A CN115003319B CN 115003319 B CN115003319 B CN 115003319B CN 202080092637 A CN202080092637 A CN 202080092637A CN 115003319 B CN115003319 B CN 115003319B
Authority
CN
China
Prior art keywords
antibody
seq
sequence
cancer
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080092637.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN115003319A (zh
Inventor
B·C·梁
S·鲁伊斯
C·J·法里纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abby Center Co ltd
Original Assignee
Abby Center Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abby Center Co ltd filed Critical Abby Center Co ltd
Publication of CN115003319A publication Critical patent/CN115003319A/zh
Application granted granted Critical
Publication of CN115003319B publication Critical patent/CN115003319B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080092637.1A 2019-11-12 2020-11-12 用于治疗癌症的方法和组合物 Active CN115003319B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934078P 2019-11-12 2019-11-12
US62/934078 2019-11-12
PCT/US2020/060309 WO2021097146A1 (en) 2019-11-12 2020-11-12 Methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
CN115003319A CN115003319A (zh) 2022-09-02
CN115003319B true CN115003319B (zh) 2026-03-31

Family

ID=75912868

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092637.1A Active CN115003319B (zh) 2019-11-12 2020-11-12 用于治疗癌症的方法和组合物

Country Status (7)

Country Link
US (1) US12570731B2 (cg-RX-API-DMAC10.html)
EP (1) EP4058042A4 (cg-RX-API-DMAC10.html)
JP (1) JP7722989B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220131222A (cg-RX-API-DMAC10.html)
CN (1) CN115003319B (cg-RX-API-DMAC10.html)
CA (1) CA3160636A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021097146A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN121102464B (zh) * 2025-09-19 2026-08-11 深圳市中佳生物医疗科技有限公司 一种小分子调节剂通过促进epc细胞分化改善aki治疗的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2240156A2 (en) 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
US20090311271A1 (en) 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
AU2010210312A1 (en) 2009-02-09 2011-08-04 Patrys Limited SAM-6 variants, target and methods of use
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
US8729240B2 (en) 2010-04-28 2014-05-20 National University Corporation Hokkaido University Monoclonal antibody against oxidized low-density lipoprotein
WO2011160845A2 (en) * 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
CN105358708B (zh) * 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US10858422B2 (en) * 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2017210360A1 (en) * 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019210207A2 (en) 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
WO2019232070A1 (en) * 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of psoriasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Low profile high value target: The role of OxLDL in cancer》;Albert V. Bitorina;《Biochimica Et Biophysica Acta》;20190831;第1864卷(第12期);第1-24页 *

Also Published As

Publication number Publication date
WO2021097146A1 (en) 2021-05-20
KR20220131222A (ko) 2022-09-27
EP4058042A1 (en) 2022-09-21
US20220403013A1 (en) 2022-12-22
JP2023500409A (ja) 2023-01-05
EP4058042A4 (en) 2023-12-27
WO2021097146A9 (en) 2021-08-05
US12570731B2 (en) 2026-03-10
JP7722989B2 (ja) 2025-08-13
CA3160636A1 (en) 2021-05-20
CN115003319A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
US20240016928A1 (en) Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
KR101949891B1 (ko) C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
JP7575102B2 (ja) Ｍｕｃ１８に特異的な抗体
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2026048672A (ja) Ｂａｆｆ－ｒ抗体及びその使用
BRPI0922885B1 (pt) Anticorpo humano que se liga especificamente à próproteina convertase subtilisina/kexina tipo 9 (hpcsk9) humana, molécula de ácido nucleico isolada, vetor de expressão, método para produzir o referido anticorpo e composição farmacêutica
KR102928177B1 (ko) Abcb5 리간드 및 기질
KR20100110841A (ko) 배합물
EP4530297A1 (en) Anti-asgr1 monoclonal antibody and use thereof
CN115003319A (zh) 用于治疗癌症的方法和组合物
CN107759691B (zh) 一种特异性结合axl的单克隆抗体
US11464784B2 (en) Inhibition of aminocylase 3 (AA3) in the treatment of cancer
CN113412282B (zh) 与白细胞介素-17A及肿瘤坏死因子-α特异性结合的双靶向抗体
CN114515335A (zh) 抗ox40抗体在治疗肿瘤或癌症中的应用
EP3856784A1 (en) Pharmaceutical combination for the treatment of cancer
KR20210121126A (ko) 골관절염의 징후 또는 증상의 치료 방법
KR20170023414A (ko) 간세포 암종을 위한 항-ｖｅｇｆｒ2 항체 요법
WO2022195504A1 (en) Method of treating osteoarthritis pain with an anti ngf antibody
WO2025006989A2 (en) Methods for detection and treatment of cancer
WO2024119068A2 (en) S100a7 as a diagnostic marker and therapeutic target for disorders
BR122024006557A2 (pt) Métodos para produzir um anticorpo reoxidado ou fragmento de ligação ao antígeno do mesmo e para produzir um conjugado anticorpofármaco
HK40047709A (en) Abcb5 ligands and substrates

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant